• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

    3/26/24 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email

    Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.

    Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O'Day, Gilead's Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024.

    Mr. Dickinson joined Gilead in 2016. Prior to his current role as CFO, he served as head of the company's corporate development and strategy group. Before joining Gilead, Mr. Dickinson worked at Lazard as global co-head of the healthcare investment banking division. Earlier in his career, he served as general counsel and vice president of corporate development at Myogen, Inc., which was acquired by Gilead in 2006.

    Mr. Dickinson is also a member of the Board of Directors of Sutter Health.

    "On behalf of the Galapagos Board of Directors, I am very pleased to welcome Andy to our Board," said Dr. Paul Stoffels1, CEO and Chairman of Galapagos. "Andy brings valuable experience in corporate development, financial transactions and investment decision making to our Board as we continue to position our company for value creation for all our stakeholders. The Board and I also want to sincerely thank Dan for his valuable contributions to the Galapagos Board of Directors."

    "I am honored to step into Dan's role as a member of the Galapagos Board of Directors," said Mr. Dickinson. "I look forward to working with the team and to contributing to the company's mission of pioneering on behalf of patients and accelerating innovation to address important medical needs."

    About Galapagos

    We are a biotechnology company with operations in Europe and the US dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized, point-of-care CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. For additional information, please visit www.glpg.com or follow us on LinkedIn or X (formerly Twitter). 

    Contacts

    Media inquiries

    Marieke Vermeersch 

    +32 479 490 603 

    [email protected]  
    Investor inquiries 

    Sofie Van Gijsel 

    +1 781 296 1143

    [email protected]



    Sandra Cauwenberghs 

    +32 495 58 46 63 

    [email protected]

    Forward-looking statements

    This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "will," "long-term," and "forward," and any similar expressions. These statements include, but are not limited to, statements regarding the appointment of a new director. Any forward-looking statements in this press release are based on our management's current expectations and beliefs, and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties and other factors which might cause our actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties and other factors include, without limitation, the risk that we may not be able to realize the expected benefits from the appointment of the new director. A further list and description of these risks, uncertainties and other factors can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20‐F filed with the SEC, as supplemented and/or modified by any other filings and reports that we have made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if our results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. We expressly disclaim any obligation to update any forward-looking statements in this press release, unless required by law or regulation.


    1 Throughout this press release, ‘Dr. Paul Stoffels' should be read as ‘Dr. Paul Stoffels, acting via Stoffels IMC BV'.

    Attachment

    • PR BoD changes_March 2024_ENG_Final


    Primary Logo

    Get the next $GLPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    8/24/2023Buy → Neutral
    Citigroup
    5/5/2023Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GLPG
    Leadership Updates

    Live Leadership Updates

    See more
    • Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

      Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.  The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and

      3/27/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

      Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value.  "We are pleased to welcome Oleg Nodelman to the Galapagos Board," said Dr. Paul Stoffels, Galapagos' CEO and Chair of the Board of Direc

      10/7/24 1:00:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

      Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders' Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of t

      3/28/24 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Announces Executive Leadership Updates

      Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo  Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements. In line with its planned separation

      4/21/25 4:10:00 PM ET
      $GLPG
      $NMRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

      Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months.Paul Stoffels1, MD, CEO and Chair of the B

      4/15/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    SEC Filings

    See more
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/29/25 4:44:24 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/23/25 5:19:27 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/21/25 5:30:59 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galapagos NV

      SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

      11/12/24 9:55:16 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Galapagos NV

      SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

      10/8/24 4:35:06 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Galapagos NV

      SC 13D - GALAPAGOS NV (0001421876) (Subject)

      8/23/24 4:01:26 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galapagos NV downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

      2/14/25 8:06:36 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos NV downgraded by Kepler

      Kepler downgraded Galapagos NV from Hold to Reduce

      11/20/24 7:41:53 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Galapagos NV with a new price target

      Leerink Partners initiated coverage of Galapagos NV with a rating of Market Perform and set a new price target of $24.00

      9/9/24 7:50:07 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Financials

    Live finance-specific insights

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

      Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G

      2/12/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

      Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL

      1/8/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care